Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Study Identifies Potential Therapeutic Target for Incurable, Rare Type of Soft-Tissue Cancer

Published: Friday, December 27, 2013
Last Updated: Thursday, December 26, 2013
Bookmark and Share
UT Southwestern scientists study published online in Cell Reports.

A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report.

In the study, published online in Cell Reports, scientists found that inhibiting the action of a protein called BRD4 caused cancer cells to die in a mouse model of malignant peripheral nerve sheath tumors (MPNSTs).

“This study identifies a potential new therapeutic target to combat MPNST, an incurable type of cancer that is typically fatal,” said Dr. Lu Le, Assistant Professor of Dermatology at UT Southwestern and senior author of the study. “The findings also provide important insight into what causes these tumors to develop.”

MPNSTs are highly aggressive sarcomas that form around nerves. These tumors can develop sporadically, but about half of cases are in patients with a genetic disorder called neurofibromatosis type 1 (NF1) that affects 1 in 3,500 people. About 10 percent of NF1 patients will develop MPNST, which usually evolves from a benign but often large and disfiguring tumor called a plexiform neurofibroma.

Up to now, the preferred treatment for MPNST has been surgical removal, but that oftentimes is difficult or impossible due to the tumor’s location around nerves. Radiation and chemotherapy are other options, but their effectiveness is limited. The five-year survival rate for MPNST patients is about 50 percent.

By studying changes in cells as they evolved into cancerous MPNSTs, researchers in Dr. Le’s laboratory were able to determine that BRD4, a bromodomain protein that binds to DNA to regulate gene activation, is expressed at an unusually high level in MPNST cancer cells.

This action caused another protein called BCL-2 to keep cancer cells from dying. Alternately, when researchers inhibited BRD4 either genetically in the mice or pharmacologically by administering a compound called JQ1, the tumors shrank.

“These treatments suppressed tumor growth and caused the cancer cells to undergo apoptosis, or cell death. This is why BRD4 inhibition is exquisitely effective against MPNSTs and may represent a paradigm shift in therapy for these patients,” Dr. Le said.

The same class of drug used in the experiments is currently being evaluated in phase 1 and 2 trials for treatment of leukemia and a subtype of lung cancer. Meanwhile, UT Southwestern is working with a pharmaceutical company to develop a similar BRD4-inhibiting drug to launch a clinical trial for MPNST patients.

New drugs are desperately needed to treat MPNST and provide hope to NF1 patients at highest risk for this cancer, said Dr. Le, who also serves as Co-director of UT Southwestern’s Comprehensive Neurofibromatosis Clinic. The clinic offers neurofibromatosis patients access to the latest clinical trials and treatments.

Co-directed by Dr. Laura Klesse, Assistant Professor of Pediatrics, the clinic is part of the Harold C. Simmons Comprehensive Cancer Center and serves patients with all three types of hereditary neurofibromatosis, including the dominant NF1 type and rarer NF2 and Schwannomatosis forms.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Saturday, October 10, 2015
UT Southwestern Biochemist Receives NIH Early Independence Award
Dr. William Israelsen studies on hibernation may aid the fight against cancer.
Wednesday, October 07, 2015
Researchers Discover Molecule that Accelerates Tissue Regeneration
Newly discovered molecule, SW033291 accelerate cell recovery following bone marrow transplants.
Friday, June 12, 2015
UT Southwestern Faculty Members Named HHMI Investigators
Appointment of Dr. Kim Orth and Dr. Joshua Mendell to HHMI.
Saturday, May 23, 2015
Scientists Identify Key Receptors Behind Development of AML
Blocking ITIM-receptor signaling in combination with conventional therapies may represent a novel strategy for AML treatment.
Saturday, May 02, 2015
Study Reveals Molecular Genetic Mechanisms Driving Breast Cancer Progression
The findings are published online and in the journal Molecular Cell.
Saturday, April 04, 2015
New Cyclotron Facility at UT Southwestern
Expands research opportunities and imaging capabilities for detecting, tracking cancer.
Friday, March 20, 2015
Acetate Supplements Shown to Speed Up Cancer Growth
A major compound produced in the gut by host bacteria.
Friday, February 20, 2015
MAGE Genes Provide Insight into Optimizing Chemotherapy
UT Southwestern Medical Center scientists have identified a new biomarker that could help identify patients who are more likely to respond to certain chemotherapies.
Tuesday, February 17, 2015
Researchers Identify ‘Achilles heel’ in Metabolic Pathway
Achilles heel could lead to new lung cancer treatments.
Saturday, February 14, 2015
Study Links Deficiency of Cellular Housekeeping Gene with Aggressive Forms of Breast Cancer
Research team studies genes involved in the autophagy process and their roles in cancer, aging, infections, and neurodegenerative diseases.
Saturday, January 31, 2015
Targeting The Cell’s ‘Biological Clock’
Researchers target the cell’s ‘biological clock’ in promising new therapy to kill cancer cells, shrink tumor growth.
Monday, January 05, 2015
Whole-Genome Sequencing Successfully Identifies Cancer-Related Mutations
UT Southwestern Medical Center cancer researchers have demonstrated that whole-genome sequencing can be used to identify patients’ risk for hereditary cancer.
Wednesday, December 24, 2014
Scientists Identify New and Beneficial Function of Endogenous Retroviruses
Researchers found that ERV play a critical role in the body’s immune defense against common bacterial and viral pathogens.
Friday, December 19, 2014
Signaling Mechanism Could Be Target For Survival, Growth Of Tumor Cells In Brain Cancer
Non-canonical EGFR signalling shown to make glioblastoma tumor cells more resistant to chemotherapy treatment.
Monday, December 15, 2014
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos